Tag: <span>Cancer Therapy</span>

Home / Cancer Therapy
Post

Engineered strain reveals key mechanism behind bacterial cancer therapy

by Chinese Academy of Sciences Cancer cell during cell division. Credit: National Institutes of Health A research team has elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain. Their findings were published in Cell. Exploring the use of antitumor bacteria in cancer therapy dates back to the 1860s. Despite this long history, however, clinical application of bacterial-based...

Post

MYCN and MDM2: A transformative strategy in cancer therapy

Peer-Reviewed Publication Compuscript Ltd FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image:  The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with Myc-associated factor X (MAX). Downstream gene expression contributes to oncogenic functions by promoting proliferation, inhibiting apoptosis, stimulating pluripotency, promoting embryogenesis,...

Post

Molecular crowbar’ protein degradation strategy offers new hope in cancer therapy

by University of California – Riverside Cartoon illustrates the research. Credit: Isaac Rodriguez, UC Riverside. In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A University of California, Riverside team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer development....

Post

Unlocking the potential of bispecific antibody-drug conjugates for targeted cancer therapy

by Frontiers Journals Credit: Unsplash/CC0 Public Domain Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a ‘magic bullet’ strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs. The evolution of ADCs has seen significant advancements from first-generation Mylotarg, which was initially approved and later withdrawn...

FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
Post

FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma

by Sarah Gantz, The Philadelphia Inquirer Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug Administration announced an investigation into whether the treatment may cause cancer in rare cases. Chimeric...

Cancer therapy shows promise against tuberculosis
Post

Cancer therapy shows promise against tuberculosis

by Texas Biomedical Research Institute Credit: Biomedicine & Pharmacotherapy (2023). DOI: 10.1016/j.biopha.2023.115738A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute (Texas Biomed) have found that the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The...

Common blood thinner may double as cancer therapy
Post

Common blood thinner may double as cancer therapy

by Columbia University Irving Medical Center Credit: Cell Metabolism (2023). DOI: 10.1016/j.cmet.2023.06.014 Warfarin, a widely used blood thinner, appears to have potent anti-cancer properties, according to a study by Columbia University researchers. The study, conducted in human cells and in mice, found that warfarin stops tumors from interfering with a self-destruct mechanism that cells initiate when they detect mutations...

Rethinking the protein inhibitor approach to cancer therapy
Post

Rethinking the protein inhibitor approach to cancer therapy

by Stony Brook University Two-step strategy for repeatable site-specific gene circuit integration. a, Network diagram of regulatory interactions and phenotypic impacts for native and ectopic BACH1. ‘BACH1e’ indicates the ectopic BACH1 gene introduced and controlled via the mNF gene circuit, whereas ‘BACH1n’ indicates the native BACH1 gene; ‘BACH1p’ indicates the BACH1 protein. The same notation applies to...

  • 1
  • 2
  • 5